Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Core Viewpoint - Madrigal Pharmaceuticals, Inc. will participate in the J.P. Morgan Annual Healthcare Conference on January 12, 2026, at 1:30 PM PST, with a live broadcast available for investors [1] Company Overview - Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with significant unmet medical needs [2] - The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist that targets key underlying causes of MASH [2] - Rezdiffra is the first and only medication approved by both the FDA and the European Commission for treating MASH with moderate to advanced fibrosis (F2 to F3) [2] - An ongoing Phase 3 outcomes trial is assessing Rezdiffra for the treatment of compensated MASH cirrhosis (F4c) [2]